A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group

Gynecologic Oncology

Volumn 111, Issue 1, 2008, Pages 22-26

  Garcia, Agustin A ^a   Blessing, John A ^b   Nolte, Susan ^c   Mannel, Robert S ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ABINGTON MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Docetaxel; Endometrial cancer; Phase II

Indexed keywords

DEXAMETHASONE; DOCETAXEL; ERYTHROPOIETIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; EDEMA; ENDOMETRIUM CARCINOMA; EVENING DOSAGE; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING DISORDER; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LUNG DISEASE; METABOLIC DISORDER; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SEPSIS; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TAXOIDS;

EID: 52049093896     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.06.013     Document Type: Article

References (24)

1. Jemal A., et al. Cancer Statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
2. Thigpen J.T., Buchsbaum H., Mangan C., et al. Phase II study of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Cancer Treat. Rep. 63 (1979) 21-27
3. Thigpen J.T., Blessing J.A., Lagasse L.D., et al. Phase II trial of cisplatin as second line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Am. J. Clin. Oncol. 7 (1984) 253-257
4. Thigpen J.T., Blessing J.A., Homesley J., et al. Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 33 (1989) 68-72
5. Ball H.G., Blessing J.A., Lentz S.S., and Mutch D.G. A phase II trial of paclitaxel inpatients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol. Oncol. 62 (1996) 278-281
6. Cortes J., and Pazdur R. Docetaxel. J. Clin. Oncol. 13 (1995) 2643-2655
7. Jones S.E., Erban J., Overmeyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 23 (2005) 5542-5551
8. Vasey P.A., Jayson G.C., Gordon A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004) 1682-1691
9. Valero V., Jones S.E., Von Hoff D.D., et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J. Clin. Oncol. 16 (1998) 3362-3368
10. Rose P.G., Blessing J.A., Ball H.G., et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88 (2003) 130-135
11. Harvey V., Mouridsen H., Semiglazov V., et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J. Clin. Oncol. 24 (2006) 4963-4970
12. Katsumata N., Noda K., Nozawa S., et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br. J. Cancer 93 (2005) 999-1004
13. Gunthert A.R., Ackermann S., Beckmann M.W., Camara O., Kiesel L., and Rensing K. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. Gynecol. Oncol. 104 (2007) 86-90
14. Hainsworth J.D., Burris H.A., Erland J.B., et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol. 16 (1998) 2165-2168
15. Hainsworth J.D., Burris III H.A., Yardley D.A., et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J. Clin. Oncol. 19 (2001) 3500-3505
16. Chen T.T., and Ng T.H. Optimal flexible designs in phase II clinical trials. Stat. Med. 17 (1998) 2301-2312
17. Humber C.E., Tierney J.F., Symonds R.P., et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann. Oncol. 18 (2007) 409-420
18. Carey M.S., Gawlik C., Fung-Kee-Fung M., et al. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol. Oncol. 101 (2006) 158-167
19. Fleming G.F., Brunetto V.L., Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 22 (2004) 2159-2166
20. Price F.V., Edwards R.P., Kelley J.L., Kunschner A.J., and Hart L.A. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin. Oncol. 24 5 Suppl 15 (1997) S15-78-S15-82
21. Michener C.M., Peterson G., Kulp B., Webster K.D., and Markman M. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. Cancer Res. Clin. Oncol. 131 (2005) 581-584
22. Tinker A.V., Gebski V., Fitzharris B., et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01. Gynecol. Oncol. 104 (2007) 647-653
23. Lincoln S., Blessing J.A., Lee R.B., and Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88 (2003) 277-281
24. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. New Engl. J. Med. 358 (2008) 1663-1671